Skip to main content
U.S. flag

An official website of the United States government

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.

Towards Clinical Application of Methylated DNA Sequences as Cancer Biomarkers: A Joint NCI s EDRN & NIST Workshop on Standards, Methods, Assays, Reagents and Tools (SMART)

Published

Author(s)

J Kagan, S Srivastava, Peter E. Barker, S Belinsky, P Cairns

Abstract

Numerous studies have demonstrated the promise of DNA methylation of cancer genes as potential biomarkers for clinical application in the risk, diagnosis and prognosis of cancer. Barriers to more rapid validation and application include the selection of target gene sequence, the choice and processing of clinical specimen, and the methodology and technology used for analysis. We present here a summary of the main issues and current challenges, as well as outcomes and recommendations, for the use of methylated DNA sequences as cancer biomarkers that arose from discussions held at the NCI EDRN and NIST Workshop in Bethesda, 2005.
Citation
Journal of the National Cancer Institute

Citation

Kagan, J. , Srivastava, S. , Barker, P. , Belinsky, S. and Cairns, P. (2021), Towards Clinical Application of Methylated DNA Sequences as Cancer Biomarkers: A Joint NCI s EDRN & NIST Workshop on Standards, Methods, Assays, Reagents and Tools (SMART), Journal of the National Cancer Institute (Accessed April 23, 2024)
Created October 12, 2021